1
Clinical Trials associated with Melan-A VLP vaccine(Centre Hospitalier Universitaire Vaudois)Phase I Study of In Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, may be used to prepare the body for other treatments, such as cellular adoptive immunotherapy. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. Giving cyclophosphamide together with fludarabine followed by biological therapy may be an effective treatment for metastatic melanoma.
PURPOSE: This phase I trial is studying the side effects of giving cyclophosphamide together with fludarabine followed by cellular adoptive immunotherapy, and vaccine therapy in treating patients with metastatic melanoma.
100 Clinical Results associated with Melan-A VLP vaccine(Centre Hospitalier Universitaire Vaudois)
100 Translational Medicine associated with Melan-A VLP vaccine(Centre Hospitalier Universitaire Vaudois)
100 Patents (Medical) associated with Melan-A VLP vaccine(Centre Hospitalier Universitaire Vaudois)
100 Deals associated with Melan-A VLP vaccine(Centre Hospitalier Universitaire Vaudois)